ReviewCurrent opinion in organ transplantation2013
Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: lessons from the initial clinical trials.
Review in Current opinion in organ transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use.World journal of stem cells · 2023Review
- Mesenchymal Stem/Stromal Cells in Organ Transplantation.Pharmaceutics · 2022Review
- Biophysical phenotyping of mesenchymal stem cells along the osteogenic differentiation pathway.Cell biology and toxicology · 2021Review
- Stem Cell Niche Microenvironment: Review.Bioengineering (Basel, Switzerland) · 2021Review
- Adipose-derived cellular therapies prolong graft survival in an allogenic hind limb transplantation model.Stem cell research & therapy · 2021Article
- iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants.Stem cell research & therapy · 2019Article
- Effect of Comedications and Endotoxins on Mesenchymal Stem Cell Secretomes, Migratory and Immunomodulatory Capacity.Journal of clinical medicine · 2019Article
- Designing stem cell niches for differentiation and self-renewal.Journal of the Royal Society, Interface · 2018Review
- Delivery of Exogenous miR-124 to Glioblastoma Multiform Cells by Wharton's Jelly Mesenchymal Stem Cells Decreases Cell Proliferation and Migration, and Confers Chemosensitivity.Stem cell reviews and reports · 2018Article
- Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence.Stem cells international · 2016Review
- Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease.Annals of biomedical engineering · 2015Review
- Development of an encapsulated stem cell-based therapy for diabetes.Expert opinion on biological therapy · 2015Review
- Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles.Frontiers in immunology · 2014Review
- Mesenchymal stromal cell secreted sphingosine 1-phosphate (S1P) exerts a stimulatory effect on skeletal myoblast proliferation.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewDiscuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT). RECENT
findingsTissue repair and immunomodulatory properties have been recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation was associated with improved graft function, reduced rejection, ability to omit induction and/or lower maintenance immunosuppression regimen, as well as to treat rejection episodes. SUMMARY: We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies including MSC to improve SOT outcomes. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.